Nasdaq
$2.32▲ 0.43%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $505.1MShares out 2.200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
12- 10.16After-hours26.10.17 08:404/AOwnership#●●●
CytomX Therapeutics, Inc.
CytomX Therapeutics insider McCarthy Sean A. has filed a Form 4/A to amend a previously reported statement of changes in beneficial ownership of securities dated November 6, 2025. This filing serves to correct the details regarding the insider's equity holdings.…more
$2.32+0.43%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.7Pre-market26.08.07 22:20SCHEDULE 13GOwnership
CytomX Therapeutics, Inc.
스테이트 스트리트(State Street Corp)가 사이토맥스 테라퓨틱스(CytomX Therapeutics, Inc.)의 지분 5% 이상을 보유한 주요 주주로서 Schedule 13G 공시를 제출했습니다. 이는 기관 투자자가 해당 기업의 지분을 대량으로 확보했음을 공식화한 것입니다.…more
$2.32+0.43%vs prev closeView filingShare - 8.6After-hours26.08.07 05:23S-8Offering
CytomX Therapeutics, Inc.
CytomX Therapeutics는 2026년 6월 17일 계획 수정에 따라 총 750만 주의 보통주를 신규 등록했습니다. 이번 등록은 2015년 주식 인센티브 플랜에 650만 주, 종업원 주식 매수 플랜(ESPP)에 100만 주를 추가하여 향후 임직원 보상 및 주식 매수를 위해 발행될 예정입니다.…more
$2.32+0.43%vs prev closeView filingShare
11 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.1Pre-market26.09.01 21:00#●●●#●●●
CytomX Therapeutics to Present at Upcoming September Investor Conferences…more
CytomX Therapeutics announced that its management will participate in several healthcare investor conferences throughout September. This is a routine investor relations activity and does not provide new material information regarding the company's financial or clinical status.…more
$2.32+0.43%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 8.27Pre-market26.08.27 21:00
●●●●●●●● ●●●●● ●●●●●●
CytomX Therapeutics announced that its colorectal cancer drug candidate, Varseta-M, has been granted Fast Track Designation by the FDA. The company plans to initiate a registrational clinical trial for the treatment in the first half of 2027.…more
$2.32+0.43%vs prev close - 8.27Pre-market26.08.27 21:01
●●●●●●●● ●●●●● ●●●●●●
CytomX Therapeutics has been granted FDA Fast Track designation for its metastatic colorectal cancer treatment candidate. The company plans to initiate a registrational monotherapy study in the first half of 2027.…more
$2.32+0.43%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report